Biomea Fusion, located in Redwood City, CA, is a biopharmaceutical company dedicated to the discovery and development of covalent small molecules for the treatment of genetically defined cancers and metabolic diseases. Their innovative approach involves using synthetic compounds that form permanent bonds to target proteins, offering several advantages over traditional non-covalent drugs. With their proprietary FUSION™ System platform, Biomea Fusion leverages their expertise in covalent binding chemistry to advance a pipeline of novel covalent therapies.

Their lead product candidate, BMF-219, is an orally bioavailable inhibitor of MENIN, a key transcriptional regulator in oncogenic signaling. Biomea Fusion's goal is to become a leader in developing covalent small molecules, maximizing the depth and durability of clinical benefits for patients with various cancers. Their name, derived from Greek and Latin words meaning life and my, reflects their mission to improve individuals' lives through the development of patient-friendly medicines.

Led by CEO Thomas Butler and President Ramses Erdtmann, the company is driven by the desire to achieve cures for patients and bring them back to a normal quality of life. By focusing on covalently bound therapies, Biomea Fusion aims to provide long-lasting and effective treatments while minimizing side effects. Their dedication to innovation and patient-centric care sets them apart in the field of oncology drug development